Previous 10 | Next 10 |
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice pre...
2023-08-14 15:22:00 ET Summary Two new Breakout Stocks for Week 33 curated by the MDA model for 10% short-term upside along with one Dow pick. Last week two of four picks gained over the 10% mark in less than a week with peak gains in EHTH +12.3% and ATEX +15.4% still near highs. ...
2023-07-29 00:22:52 ET Summary Axonics Inc. has grown its valuation to $2.7 billion in the healthcare equipment industry. The company focuses on developing products for the treatment of bladder and bowel dysfunctions. Recent developments include acquiring technology for easier...
2023-07-28 12:46:30 ET Shares of Axonics (NASDAQ: AXNX) were up more than 10% at noon on Friday after the medical device company released second-quarter earnings. The healthcare stock is down more than 6% so far this year. Axonics focuses on medical products to treat bladder...
2023-07-27 23:27:09 ET Axonics, Inc. (AXNX) Q2 2023 Earnings Conference Call July 27, 2023 16:30 ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Off...
2023-07-27 16:14:52 ET Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q2 GAAP EPS of -$0.15. Revenue of $92.9M. Sees 2023 total company revenue of $358 million, an increase of 31% compared to fiscal year 2022. For further details see: Axonics...
Generated quarterly revenue of $92.9 million, an increase of 35% year over year Fiscal year 2023 revenue guidance increased to $358 million Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment o...
2023-07-26 17:35:57 ET Axonics Modulation Technologies ( NASDAQ: AXNX ) is scheduled to announce Q2 earnings results on Thursday, July 27th, after market close. The consensus EPS Estimate is -$0.09 (+80.9% Y/Y) and the consensus Revenue Estimate is $86.26M (+25.0% Y/Y). ...
2023-07-17 05:36:22 ET Summary Two new Breakout Stocks for Week 29 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are at +126.4% YTD. Last week 3 out of 4 picks gained over 13.4% with peak gains in KODK +23.8%, SMCI +19.2%, YMM +13.4%...
2023-07-14 11:54:56 ET Axonics, ( NASDAQ: AXNX ) and Shockwave Medical ( NASDAQ: SWAV ) moved in opposite directions Friday after the Centers for Medicare & Medicaid Services (CMS) proposed changes to 2024 Medicare reimbursement rates for hospital outpatient department...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...